Integra Lifesciences Holdings (IART) Shareholder Champlain Investment Partners LLC Has Upped Its Position by $4.40 Million

Investors sentiment increased to 1.32 in 2019 Q2. Its up 0.05, from 1.27 in 2019Q1. It is positive, as 20 investors sold IART shares while 65 reduced holdings. 39 funds opened positions while 73 raised stakes. 68.86 million shares or 0.56% less from 69.24 million shares in 2019Q1 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) holds 4,221 shares. New York State Teachers Retirement System accumulated 74,458 shares or 0.01% of the stock. Meeder Asset invested in 0% or 95 shares. Cornercap Investment Counsel stated it has 0.15% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Ubs Asset Americas owns 0% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 86,481 shares. 5,041 are owned by Ls Advsr Ltd Co. The Virginia-based Burney has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Atlanta Capital Mngmt L L C holds 0.17% in Integra LifeSciences Holdings Corporation (NASDAQ:IART) or 685,995 shares. Aqr Lc owns 11,805 shares. Stone Ridge Asset Mngmt Lc holds 0.08% in Integra LifeSciences Holdings Corporation (NASDAQ:IART) or 24,648 shares. Fmr Ltd reported 2.52M shares. Texas-based Texas Permanent School Fund has invested 0.04% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Geode Lc stated it has 0.01% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Ny State Common Retirement Fund holds 135,700 shares. Moreover, Fisher Asset Limited Liability Com has 0.05% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 781,166 shares.

Champlain Investment Partners Llc increased its stake in Integra Lifesciences Holdings (IART) by 1.98% based on its latest 2019Q2 regulatory filing with the SEC. Champlain Investment Partners Llc bought 88,031 shares as the company’s stock rose 24.59% . The institutional investor held 4.54 million shares of the laboratory analytical instruments company at the end of 2019Q2, valued at $228.96M, up from 4.45 million at the end of the previous reported quarter. Champlain Investment Partners Llc who had been investing in Integra Lifesciences Holdings for a number of months, seems to be bullish on the $5.20B market cap company. The stock increased 2.89% or $1.71 during the last trading session, reaching $60.84. About 315,967 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 3.56% since October 12, 2018 and is uptrending. It has outperformed by 3.56% the S&P500.

Champlain Investment Partners Llc, which manages about $6.04B and $8.47 billion US Long portfolio, decreased its stake in Icu Medical Inc. (NASDAQ:ICUI) by 127,921 shares to 375,170 shares, valued at $69.73M in 2019Q2, according to the filing. It also reduced its holding in Abiomed Inc. (NASDAQ:ABMD) by 23,710 shares in the quarter, leaving it with 239,575 shares, and cut its stake in Cooper Companies Inc. (NYSE:COO).

More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: which released: “Integra LifeSciences to Host Second Quarter 2019 Earnings Results Conference Call on July 24, 2019 – GlobeNewswire” on July 10, 2019, also with their article: “”Integra LifeSciences partners with Tissue Analytics to advance data analytics in wound care clinical trials” – PRNewswire” published on July 08, 2019, published: “Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates – Yahoo Finance” on July 24, 2019. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: and their article: “When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)? – Yahoo Finance” published on May 05, 2019 as well as‘s news article titled: “Integra LifeSciences Prices Public Offering of Common Stock – GlobeNewswire” with publication date: May 09, 2018.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.